Compositions and methods for targeted delivery to cells
US-2024390271-A1 · Nov 28, 2024 · US
Ubiquitin variant modulators of HECT E3 ligases and their uses
US10618943B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10618943-B2 |
| Application number | US-201715436399-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 17, 2017 |
| Priority date | Feb 17, 2016 |
| Publication date | Apr 14, 2020 |
| Grant date | Apr 14, 2020 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention provides ubiquitin variants that specifically bind to HECT E3 ligases, and methods of using these variants to modulate the activity of HECT E3 ligases.
First claim
Opening claim text (preview).
What is claimed is: 1. A ubiquitin variant (Ubv) polypeptide that binds to NEDD4L, wherein the sequence of said Ubv polypeptide comprises a sequence selected from the group consisting of SEQ ID NOs:9-12. 2. A Ubv polypeptide that binds to SMURF2 (S2), wherein the sequence of said Ubv polypeptide comprises a sequence that is at least 90% identical to a sequence selected from the group consisting of SEQ ID NOs:18-22. 3. The Ubv polypeptide of claim 2 , wherein the sequence of said Ubv polypeptide comprises a sequence selected from the group consisting of SEQ ID NOs:18-22. 4. A Ubv polypeptide that binds to HACE1 (HA), wherein the sequence of said Ubv polypeptide comprises a sequence that is at least 90% identical to a sequence selected from the group consisting of SEQ ID NOs:54-56. 5. The Ubv polypeptide of claim 4 , wherein the sequence of said Ubv polypeptide comprises a sequence selected from the group consisting of SEQ ID NOs:54-56. 6. A Ubv polypeptide that binds to WWP2 (P2), wherein the sequence of said Ubv polypeptide comprises a sequence that is at least 90% identical to a sequence selected from the group consisting of SEQ ID NOs:27-30. 7. The Ubv polypeptide of claim 6 , wherein the sequence of said Ubv polypeptide comprises a sequence selected from the group consisting of SEQ ID NOs:27-30.
Assignees
Inventors
Classifications
Transferases (2.) (ribonucleases C12N9/22) · CPC title
- C07K14/47Primary
from mammals · CPC title
Ligases (6) · CPC title
Ubiquitin-protein ligase (6.3.2.19), i.e. ubiquitin-conjugating enzyme · CPC title
Liquid chromatography · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10618943B2 cover?
- The invention provides ubiquitin variants that specifically bind to HECT E3 ligases, and methods of using these variants to modulate the activity of HECT E3 ligases.
- Who is the assignee on this patent?
- Governing Council Univ Toronto
- What technology area does this patent fall under?
- Primary CPC classification C07K14/47. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Apr 14 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).